Medtronic (NYSE:MDT) today announced data from the ALERT trial aimed at addressing health disparities in structural heart care.

March 27 (Reuters) - Medtronic said on Friday the U.S. Food and Drug Administration has cleared its surgical system for ...

Medtronic (NYSE:MDT) announced the launch of the EMBRACE trial of its Symplicity Spyral renal denervation (RDN) system.

Medtronic is a stable medical device company currently trading below analyst price targets and undervalued, with a potential ...

Medtronic (MDT) has cut its full-year earnings outlook, citing the recent IPO of its diabetes business, MiniMed Group (MMED), and the earlier-than-expected FDA approval and commercial launch of ...

Medtronic plc (NYSE:MDT) is included among the Dividend Kings and Aristocrats List: 32 Biggest Stocks. On March 24, Medtronic ...

The OmniaSecure lead gained the first U.S. approval for placement in the heart’s left bundle branch area, to help activate ...

The U.S. Court of Appeals for the Ninth Circuit ruled that Medtronic can’t be sued by a man who alleged the company’s spinal cord stimulator malfunctioned, according to a document filed March 25.

Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance of the Stealth AXiS™ surgical system for cranial and ear, nose, and ...

Merit’s ViaVerte nerve ablation system for chronic lower-back pain expands Medtronic’s lineup of chronic pain treatments.

The timing of the initial public offering and the clearance of a new insulin pump are expected to affect Medtronic’s results ...

OmniaSecure is now the first defibrillation lead approved for placement in the left bundle branch.